Skip to main content
SpringerLink
Log in

The function role and synergic effect of syndecan-1 for mifepristone in uterine leiomyoma

  • Original Article
  • Published:
Cytotechnology Aims and scope Submit manuscript

Abstract

The study intends to investigate the regulation of syndecan-1 in human uterine leiomyoma cells. Human syndecan-1 levels were detected by Western blot in uterus leimyoma's tissue. The efficacy of syndecan-1 silencing on the cell proliferation, metalloproteinases and extracellular matrix were determined through Cell Counting Kit (CCK8) assay and Western blot assay, respectively. We compared the respective and combined effect of mifepristone and syndecan-1 on cell proliferation and the expression of metalloproteinases and extracellular matrix (ECM) in human uterine leiomyoma cells. The inhibitory effects of Syndecan-1 silencing on proliferation, ECM and Matrix Metalloproteinase (MMP) were observed in human uterine leiomyoma cells. Furthermore, syndecan-1 inhibition enhanced the effects of mifepristone against uterine leiomyoma cell proliferation. The expression of MMPs and ECM components in human uterine leiomyoma cells was decreased dramatically after syndecan-1 silencing, which was promoted after mifepristone treatment. Altogether, syndecan-1 silencing enhanced the efficacy of mifepristone on the uterine leiomyoma cell proliferation and ECM formation. Therefore, targeting syndecan-1 represents a novel therapeutic strategy to treat uterine leiomyoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E, Doglioni C (2003) High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98:474–483

    Article  Google Scholar 

  • Bhowmick NA, Neilson EG, Moses HL (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432:332–337

    Article  CAS  Google Scholar 

  • Cardozo ER, Foster R, Karmon AE, Lee AE, Gatune LW, Rueda BR, Styer AK (2018) MicroRNA 21a–5p overexpression impacts mediators of extracellular matrix formation in uterine leiomyoma. Reprod Biol Endocrinol 16:46

    Article  Google Scholar 

  • Choi DS, Kim JH, Ryu HS, Kim HC, Han JH, Lee JS, Min CK (2007) Syndecan-1, a key regulator of cell viability in endometrial cancer. Int J Cancer 121:741–750

    Article  CAS  Google Scholar 

  • Chuang TD, Khorram O (2019) Cross-talk between miR-29c and transforming growth factor-β3 is mediated by an epigenetic mechanism in leiomyoma. Fertil Steril 112:1180–1189

    Article  CAS  Google Scholar 

  • Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Korc M, Friess H, Büchler MW (2000) Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer 88:12–20

    Article  CAS  Google Scholar 

  • Cui J, Jin S, Jin C, Jin Z (2020) Syndecan-1 regulates extracellular matrix expression in keloid fibroblasts via TGF-β1/Smad and MAPK signaling pathways. Life Sci 254:117326

    Article  CAS  Google Scholar 

  • Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT, Jayson GC (2004) Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res 10:5178–5186

    Article  CAS  Google Scholar 

  • Go K, Ishino T, Nakashimo Y, Miyahara N, Ookubo T, Takeno S, Hirakawa K (2010) Analysis of syndecan-1 and TGF-beta expression in the nasal mucosa and nasal polyps. Auris Nasus Larynx 37:427–435

    Article  Google Scholar 

  • Hayashida K, Johnston DR, Goldberger O, Park PW (2006) Syndecan-1 expression in epithelial cells is induced by transforming growth factor beta through a PKA-dependent pathway. J Biol Chem 281:24365–24374

    Article  CAS  Google Scholar 

  • Ibrahim SA, Yip GW, Stock C, Pan JW, Neubauer C, Poeter M, Pupjalis D, Koo CY, Kelsch R, Schule R, Rescher U, Kiesel L, Gotte M (2012) Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase- and E-cadherin-dependent mechanism. Int J Cancer 131:E884–E896

    Article  CAS  Google Scholar 

  • Joseph DS, Malik M, Nurudeen S, Catherino WH (2010) Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. Fertil Steril 93:1500–1508

    Article  CAS  Google Scholar 

  • Kato M, Saunders S, Nguyen H, Bernfield M (1995) Loss of cell surface syndecan-1 causes epithelia to transform into anchorage-independent mesenchyme-like cells. Mol Biol Cell 6:559–576

    Article  CAS  Google Scholar 

  • Laughlin SK, Schroeder JC, Baird DD (2010) New directions in the epidemiology of uterine fibroids. Semin Reprod Med 28:204–217

    Article  CAS  Google Scholar 

  • Lewis TD, Malik M, Britten J, Parikh T, Cox J, Catherino WH (2019) Ulipristal acetate decreases active TGF-β3 and its canonical signaling in uterine leiomyoma via two novel mechanisms. Fertil Steril 111:806–815

    Article  CAS  Google Scholar 

  • Liakou E, Mavrogonatou E, Pratsinis H, Rizou S, Evangelou K, Panagiotou PN, Karamanos NK, Gorgoulis VG, Kletsas D (2016) Ionizing radiation-mediated premature senescence and paracrine interactions with cancer cells enhance the expression of syndecan 1 in human breast stromal fibroblasts: the role of TGF-β. Aging (Albany NY) 8:1650–1669

    Article  CAS  Google Scholar 

  • Liebersbach BF, Sanderson RD (1994) Expression of syndecan-1 inhibits cell invasion into type I collagen. J Biol Chem 269:20013–20019

    Article  CAS  Google Scholar 

  • Lin PH, Kung HL, Chen HY, Huang KC, Hsia SM (2019) Isoliquiritigenin suppresses E2-induced uterine leiomyoma growth through the modulation of cell death program and the repression of ECM accumulation. Cancers (Basel) 11:1131

    Article  CAS  Google Scholar 

  • Liu R, Shi P, Nie Z, Liang H, Zhou Z, Chen W, Chen H, Dong C, Yang R, Liu S, Chen C (2016) Mifepristone suppresses basal triple-negative breast cancer stem cells by down-regulating KLF5 expression. Theranostics 6:533–544

    Article  CAS  Google Scholar 

  • Maheux R, Guilloteau C, Lemay A, Bastide A, Fazekas AT (1985) Luteinizing hormone-releasing hormone agonist and uterine leiomyoma: a pilot study. Am J Obstet Gynecol 152:1034–1038

    Article  CAS  Google Scholar 

  • Manon-Jensen T, Itoh Y, Couchman JR (2010) Proteoglycans in health and disease: the multiple roles of syndecan shedding. Febs J 277:3876–3889

    Article  CAS  Google Scholar 

  • Patel A, Malik M, Britten J, Cox J, Catherino WH (2016) Mifepristone inhibits extracellular matrix formation in uterine leiomyoma. Fertil Steril 105:1102–1110

    Article  CAS  Google Scholar 

  • Regős E, Abdelfattah HH, Reszegi A, Szilák L, Werling K, Szabó G, Kiss A, Schaff Z, Kovalszky I, Baghy K (2018) Syndecan-1 inhibits early stages of liver fibrogenesis by interfering with TGFβ1 action and upregulating MMP14. Matrix Biol 68–69:474–489

    Article  Google Scholar 

  • Shen Q, Zou S, Sheng B, Zhao M, Sun LZ, Zhu X (2019) Mifepristone inhibits IGF-1 signaling pathway in the treatment of uterine leiomyomas. Drug Des Dev Ther 13:3161–3170

    Article  CAS  Google Scholar 

  • Worapamorn W, Tam SP, Li H, Haase HR, Bartold PM (2002) Cytokine regulation of syndecan-1 and -2 gene expression in human periodontal fibroblasts and osteoblasts. J Periodontal Res 37:273–278

    Article  CAS  Google Scholar 

  • Yoshida S, Ohara N, Xu Q, Chen W, Wang J, Nakabayashi K, Sasaki H, Morikawa A, Maruo T (2010) Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med 28:260–273

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecology, Affiliated Maternity and Child Health Care Hospital of Nantong University, Nantong, 226018, Jiangsu, China

    Xiaoyan Shen

  2. Five Departments of Recuperation in Dalian Rehabilitation and Recuperation Center, No.30, Binhai West Road, Xigang District, Dalian City, 116013, Liaoning province, China

    Xiaoxu Wang

Authors
  1. Xiaoyan Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoxu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiaoxu Wang.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shen, X., Wang, X. The function role and synergic effect of syndecan-1 for mifepristone in uterine leiomyoma. Cytotechnology 73, 179–187 (2021). https://doi.org/10.1007/s10616-021-00455-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10616-021-00455-6

Keywords

Search

Navigation